ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
July 22 2020 - 4:20PM
Business Wire
ICON plc (NASDAQ: ICLR), a global provider
of outsourced drug and device development and commercialisation
services to pharmaceutical, biotechnology, medical device and
government and public health organisations, today announced that
all resolutions at the Annual General Meeting of the Company (AGM)
held on July 21, 2020 (which resolutions had all been recommended
by the Board) were all duly passed by shareholders. These
resolutions were set out in the Notice of the AGM sent to
shareholders dated June 9, 2020 and are available on the ICON plc
website.
The final results of the voting are as follows:
RESOLUTION NUMBER
RESOLUTION
TOTAL NUMBER OF VOTES
VOTE FOR
VOTE AGAINST
VOTE WITHHELD
1.1
To re-elect Ms. Mary
Pendergast
45,375,290
45,047,124
313,139
15,027
1.2
To re-elect Professor Hugh
Brady
45,375,290
44,847,529
512,926
14,835
1.3
To re-elect Mr. Rónán Murphy
45,375,290
44,886,771
473,815
14,704
1.4
To re-elect Ms. Julie O’Neill
45,375,290
45,352,908
6,707
15,675
2
To receive accounts and
reports
45,375,290
45,125,109
1,867
248,314
3
To authorise the fixing of the
auditors’ remuneration
45,375,290
41,855,932
3,504,170
15,188
4
To authorise the Company to allot
shares
45,375,290
45,327,330
37,054
10,906
5**
To disapply pre-emption
rights
45,375,290
45,337,113
23,998
14,179
6**
To disapply pre-emption rights
for funding capital investment or acquisitions
45,375,290
45,219,197
141,875
14,218
7**
To authorise the Company to make
market purchases of shares
45,375,290
45,072,354
178,525
124,411
8**
To authorise the price range at
which the Company can reissue shares it holds as treasury
shares
45,375,290
45,081,032
271,321
22,937
** Special Resolution. All resolutions are ordinary resolutions
unless otherwise stated.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, the impact of
COVID-19 on our business, as well as other economic and global
market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are
difficult to predict and some of which are beyond our control. For
these reasons, you should not place undue reliance on these
forward-looking statements when making investment decisions. The
word "expected" and variations of such words and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are only as of the date they are made
and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and
uncertainties relating to these forward-looking statements may be
found in SEC reports filed by ICON, including its Form 20-F, F-1,
S-8 and F-3, which are available on the SEC's website at
http://www.sec.gov.
ICON plc is a global provider of outsourced drug and device
development and commercialisation services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. The Company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
employed approximately 15,150 employees in 94 locations in 40
countries as at June 30, 2020. Further information is available at
www.iconplc.com.
Source: ICON plc Contact: Investor Relations 1 888 381
7923 or Brendan Brennan Chief Financial Officer + 353 1 291
2000 Jonathan Curtain Vice President Corporate Finance and
Investor Relations + 353 1 291 2000 All at ICON.
ICON/ICLR-F
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200722005787/en/
Investor Relations 1 888 381 7923 or Brendan Brennan Chief
Financial Officer + 353 1 291 2000 Jonathan Curtain Vice President
Corporate Finance and Investor Relations + 353 1 291 2000
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024